PSI Scientific Committee Webinar: Heart Failure Trials: Novel Estimands and Methodologies to Evaluate Therapies based on the Totality of Evidence
Heart failure (HF) is a common and global health problem affecting approx. 2% of adults in developed countries. Good news is that with new treatments on the market, HF has been converted from a short-term and quickly fatal condition to a chronic disease, which is characterized by recurrent non-fatal events (HF hospitalizations) and relatively low disease-related mortality. Classical heart failure trials have used a composite primary endpoint of cardiovascular (CV) death and HF hospitalization. This endpoint was then analyzed using a ‘time to first composite event’ analysis.
Various limitations of this endpoint have been raised in recent years. Among others, the ‘time to first composite event’ endpoint is thought to not fully capture the disease burden as it ignores all events that occur after the first event. Given that a number of recent large HF outcome trials have failed to show a clinical benefit for patients using the traditional endpoint, clinical teams are reviewing novel endpoints that better capture clinical benefit and which adapt to the changing disease profile.
In this session, we will discuss some of the recently proposed estimands and their associated analysis methods, ranging from composite endpoints of recurrent HF hospitalizations (HFH) and death to joint frailty models for recurrent HFH and death. We will illustrate these approaches based on various case-studies and discuss benefits as well as limitations from an academic, regulatory and industry perspective.
Application of Recurrent Events Methodology in Cardiovascular Trials
Dr. Brian Claggett (Harvard Medical School)
We describe a range of alternative models for recurrent events data collected in cardiovascular trials. We consider their applicability and interpretation from a medical context and illustrate them using data from a particular trial.
The Totality of Evidence: Is More the Same as Better?
Dr. Bruce Binkowitz (Merck)
Analysis of time to first event is a long held tradition for trials in the cardiovascular area, including heart failure. Yet subjects in these studies can experience more than 1 event. Recent literature has focused on utilizing all events experienced by each subject as a way of increasing efficiency through having to enroll less subjects, use less investigator sites, and save money. Consideration for examining all events further extends to measuring total patient burden, cost effectiveness, and most importantly, capturing the best picture of a subject's condition and therefore the best potential therapy. This presentation will discuss how analyzing total events isn't as simple as designing a traditional time to first event study and, for example, running an Anderson-Gill extension to a Cox PH model on all events. Examples will be taken from actual trials including a trial examining subjects with acute decompensated heart failure.
Recurrent or Multiple Event Analyses in Cardiovascular Trials
Dr. H.M. James Hung, US FDA
In cardiovascular or renal trials that we have seen in regulatory applications, major adverse clinical events are almost always assessed using analysis of time to first occurrence of the events. As some component events occur much more frequently, such as hospitalizations, during the trial, the analysis that includes all the events may improve statistical efficiency and capture disease burden of patients more properly. In this talk, I shall share a number of regulatory experiences with recurrent or multiple event analyses to give my insights into the possible values of such analysis and to stipulate the issues that need more attention.
Registration fee: None
This webinar is free of charge. However, attendees must register on the PSI website in order to obtain the dial-in details and the webinar link.
We do encourage your participation. If you have questions relating to this webinar, or any of the listed talks, ahead of the webinar, please email them to Mouna.Akacha@novartis.com
We will do our best to discuss them at the webinar.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Whatever your current challenge(s) at work, this workshop will explore what's holding you back, and how barriers can be removed in order to progress and achieve.
A PSI Training Course covering the statistical methods for repeated measures and other clustered data. Course will cover: Conditional models for continuous hierarchical data, Conditional models for continuous longitudinal data, Marginal models (GEE) for continuous longitudinal data & Discrete data.
We’re now searching at all levels for Biostatisticians and Statistical Programmers to join our International BARDS Health Technology Assessment team at our London and Zurich hubs.
The Associate Director of Biostatistics is the key client interface for all statistical issues and discussions.
In this role you will consult in the design of complex and innovative studies and clinical trial programs as well as Leading DMC/DSMB processes.
This is an excellent opportunity for someone that loves working directly with clients, contributing as a high-level project lead and key contributor.
Join our growing team and discover your extraordinary potential by working as a Covance by Labcorp Biostatistician 2 within our early phase biostatistics department.
The opportunity to combine an exciting professional career with excellent quality of life in the Cairngorms National Park area of Scotland.
Join our growing team and discover your extraordinary potential by working as a Covance by Labcorp Principal Biostatistician.
As a seasoned Biostatistician, will work primarily on Immunology: GI and Dermatology trials with a focus on Late Phase studies. Some PK Analysis experience highly desired.
As a seasoned Biostatistician, will work primarily in late phase oncology.
As an experienced pharmaceutical statistician, you will support Cytel and a client of our Functional Service Provider (FSP) division.
As a Sr Bios, you will function independently as Lead Statistician on projects and support/project statistician on others.
The Senior Manager Biostatistics will be responsible for leading biostatistics strategy and activities for a compound and/or for individual clinical studies.
As a Sr Mgr, Biostatistics you will manage a team of Statisticians and Programmers within the FSP department, as well as managing project work.
At its core, the role of a Senior Statistician at Veramed is to provide statistical support to the statistics and programming department across a range of projects, clients and therapeutic areas.
As a Senior or Principal Biotatistician, you will hold a combined project leadership and hands-on technical statistics role, working across a range of phases and therapeutic areas.
You will participate in the development of study protocols including participation in study design discussions and sample size calculations, and review CRFs and data review guidelines.
As a Senior or Principal Statistician, you will hold a combined project leadership and hands-on technical statistics role., working across a range of phases and therapeutic areas.
We are looking for passionate and motivated statisticians to work within our Services team to deliver high quality, innovative, analytical services within a clinical setting as our KerusCloud platform moves into the next phase.
Would you like to join a dynamic, growing firm where you can really make an impact, not just on the company but to accelerate drug development and ultimately benefit patients?
Opportunity to join Amgen's centre for design & analysis. We are looking for a talented Statistician to join the Global Biostatistical Science team.
